The effect of transfer factor(TF)on the treatment of advanced gastric cancer is reported in this paper. 19 cases were treated with TF and other 19 cases served as control. Therapy with TF in a dose of 2 units biw was instituted intramuscularly.24 months after operation

in the control group all patients died

while in the treated group

10 cases died and 9 survived(P<0.05). After 1 course of TF treatment( about 3 months after operation)

9 cases (75%) of the treated group turned positive (P<0.05) in PHA test

and 10 cases (90.9%) turned positive (P<0.05) in SD-SK test. In the control group

the tests remained unchanged.Percentage of E-rosette-forming cells (E-RFC) and lymphocyte transformation test(LTT) showed a significant increase after TF therapy. The average percentage of E-RFC increase from 44.3 + 8.2% to 71.4 + 9.7% (P<0.05) in 18 cases and that of LTT from 34

3+7.5% to 78.9 +6.4% (P<0.01) in 15 cases. In the control group there was no change.The preliminary results indicate that TF therapy is a valuable auzilliary means in the postoperative period of advanced gastric cancer for the improvement of general conditions and imm-unologic status of the patients